Optimizing the Use of Pneumococcal Conjugate Vaccine Globally

September 4, 2013, Vol 310, No. 9

Editorial | September 4, 2013
Optimizing the Use of Pneumococcal Conjugate Vaccine Globally
Katherine L. O’Brien, MD, MPH1
[+] Author Affiliations
JAMA. 2013;310(9):911-913. doi:10.1001/jama.2013.228062.

Initial content per JAMA convention
Pneumococcal conjugate vaccine (PCV) was first licensed in 2000 as a 7-valent product and is now available as 10- and 13-valent products (PCV10 and PCV13). As recommended by the World Health Organization,1 PCVs are now in routine use in more than 95 of 194 countries globally, including use in 27 GAVI Alliance–eligible countries and approval for use in an additional 24 such countries.2 Financial investments by individual countries and the international community, through the GAVI Alliance, are ensuring the sustainable availability of PCV in the places where it is most needed—the poorest countries where children have a substantial risk of serious illness and death from pneumococcal disease. In 2008, more than 500 000 children under 5 years died from pneumococcal disease.3 This mortality and the larger burden of serious morbidity, mostly from pneumococcal pneumonia,4 is the focus of PCV programs.